JP6448651B2 - 皮膚病の処置のためのベンゾオキサジノン誘導体 - Google Patents

皮膚病の処置のためのベンゾオキサジノン誘導体 Download PDF

Info

Publication number
JP6448651B2
JP6448651B2 JP2016544672A JP2016544672A JP6448651B2 JP 6448651 B2 JP6448651 B2 JP 6448651B2 JP 2016544672 A JP2016544672 A JP 2016544672A JP 2016544672 A JP2016544672 A JP 2016544672A JP 6448651 B2 JP6448651 B2 JP 6448651B2
Authority
JP
Japan
Prior art keywords
skin
compound
klk7
pharmaceutical composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016544672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503798A (ja
JP2017503798A5 (cg-RX-API-DMAC7.html
Inventor
ヴォーグベルグ，フレドリック
レオナルドソン，ヨーラン
Original Assignee
シクセラ ファーマ エービー
シクセラ ファーマ エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シクセラ ファーマ エービー, シクセラ ファーマ エービー filed Critical シクセラ ファーマ エービー
Publication of JP2017503798A publication Critical patent/JP2017503798A/ja
Publication of JP2017503798A5 publication Critical patent/JP2017503798A5/ja
Application granted granted Critical
Publication of JP6448651B2 publication Critical patent/JP6448651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2016544672A 2014-01-23 2015-01-22 皮膚病の処置のためのベンゾオキサジノン誘導体 Active JP6448651B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1430003-2 2014-01-23
SE1430003 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (3)

Publication Number Publication Date
JP2017503798A JP2017503798A (ja) 2017-02-02
JP2017503798A5 JP2017503798A5 (cg-RX-API-DMAC7.html) 2018-02-15
JP6448651B2 true JP6448651B2 (ja) 2019-01-09

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544672A Active JP6448651B2 (ja) 2014-01-23 2015-01-22 皮膚病の処置のためのベンゾオキサジノン誘導体

Country Status (18)

Country Link
US (2) US9695194B2 (cg-RX-API-DMAC7.html)
EP (1) EP3097085B1 (cg-RX-API-DMAC7.html)
JP (1) JP6448651B2 (cg-RX-API-DMAC7.html)
CN (1) CN106132941B (cg-RX-API-DMAC7.html)
AU (1) AU2015209761B2 (cg-RX-API-DMAC7.html)
CA (1) CA2934025C (cg-RX-API-DMAC7.html)
CY (1) CY1123477T1 (cg-RX-API-DMAC7.html)
DK (1) DK3097085T3 (cg-RX-API-DMAC7.html)
ES (1) ES2820868T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201500T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051296T2 (cg-RX-API-DMAC7.html)
LT (1) LT3097085T (cg-RX-API-DMAC7.html)
PL (1) PL3097085T3 (cg-RX-API-DMAC7.html)
PT (1) PT3097085T (cg-RX-API-DMAC7.html)
RS (1) RS60830B1 (cg-RX-API-DMAC7.html)
SI (1) SI3097085T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000557T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015112081A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6448651B2 (ja) * 2014-01-23 2019-01-09 シクセラ ファーマ エービー 皮膚病の処置のためのベンゾオキサジノン誘導体
KR102579996B1 (ko) * 2015-05-13 2023-09-18 니혼노야쿠가부시키가이샤 안트라닐산 에스테르 화합물 또는 이의 염류 및 해당 화합물을 함유하는 농원예용 살균제 및 이의 사용 방법
US10821094B2 (en) * 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
KR20250070121A (ko) * 2017-06-16 2025-05-20 아지트라 인코포레이티드 Lekti 발현 재조합 미생물을 사용하는 네테르톤 증후군의 치료를 위한 조성물 및 방법
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
JP2022549087A (ja) 2019-09-18 2022-11-24 ジェネンテック， インコーポレイテッド 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体および使用方法
CN114615984B (zh) * 2019-10-01 2025-02-07 分子皮肤治疗公司 作为klk5/7双重抑制剂的苯并噁嗪酮化合物
GB202001447D0 (en) * 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
JP2024520154A (ja) 2021-06-01 2024-05-21 シクセラ・ファーマ・アーベー ６－エトキシ－７－メトキシ－２－（２－メチルスルファニルフェニル）－３，１－ベンゾオキサジン－４－オンの水中油型乳剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
WO1999048878A1 (en) * 1998-03-24 1999-09-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
PL1631295T3 (pl) * 2003-06-06 2010-09-30 Arexis Ab Zastosowanie skondensowanych związków heterocyklicznych jako inhibitorów SCCE do leczenia chorób skóry
TWI419884B (zh) 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
JP6448651B2 (ja) * 2014-01-23 2019-01-09 シクセラ ファーマ エービー 皮膚病の処置のためのベンゾオキサジノン誘導体

Also Published As

Publication number Publication date
CA2934025A1 (en) 2015-07-30
HUE051296T2 (hu) 2021-03-01
US10072024B2 (en) 2018-09-11
ES2820868T3 (es) 2021-04-22
CN106132941A (zh) 2016-11-16
JP2017503798A (ja) 2017-02-02
US20170267692A1 (en) 2017-09-21
CY1123477T1 (el) 2022-03-24
EP3097085A4 (en) 2017-08-09
WO2015112081A1 (en) 2015-07-30
SMT202000557T1 (it) 2020-11-10
PL3097085T3 (pl) 2021-01-11
CN106132941B (zh) 2018-04-06
RS60830B1 (sr) 2020-10-30
SI3097085T1 (sl) 2020-11-30
EP3097085B1 (en) 2020-07-29
DK3097085T3 (da) 2020-10-26
CA2934025C (en) 2022-06-07
PT3097085T (pt) 2020-10-08
EP3097085A1 (en) 2016-11-30
LT3097085T (lt) 2020-10-12
US20170002021A1 (en) 2017-01-05
HRP20201500T1 (hr) 2020-12-25
AU2015209761A1 (en) 2016-07-07
US9695194B2 (en) 2017-07-04
AU2015209761B2 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
JP6448651B2 (ja) 皮膚病の処置のためのベンゾオキサジノン誘導体
Campbell Long-term neprilysin inhibition—implications for ARNIs
Swarnakar et al. Matrix metalloproteinases in health and disease: regulation by melatonin
Johnson et al. Matrix metalloproteinases
He et al. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases
Chakraborti et al. Implications of calpains in health and diseases
JP2019163296A (ja) 新しいカリクレイン７阻害剤
D Roycik et al. Matrix metalloproteinase inhibition in atherosclerosis and stroke
JP2017505299A5 (cg-RX-API-DMAC7.html)
Liu et al. Broadening horizons: exploring the Cathepsin family as therapeutic targets for Alzheimer's disease
Liu et al. Broadening horizons: exploring the cathepsin family as therapeutic targets for Alzheimer’s disease
HK1229792B (en) Benzoxazinone derivatives for treatment of skin diseases
HK1229792A1 (en) Benzoxazinone derivatives for treatment of skin diseases
Das et al. Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Yoshioka et al. Effect of hydroxamic acid‐based matrix metalloproteinase inhibitors on human gingival cells and Porphyromonas gingivalis
Georgoulas Novel methods for the modulation of wound healing after glaucoma filtration surgery
HK1229791B (zh) 新的激肽释放酶7抑制剂
JP2010209055A (ja) 医薬組成物
NAMBA et al. Influence of dexamethasone on matrix metalloproteinase production from human synovial fibroblasts in vitro
Gewirtz et al. Selective Ablation of Matrix
HK1229791A1 (en) New kallikrein 7 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181204

R150 Certificate of patent or registration of utility model

Ref document number: 6448651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250